MBX Biosciences, Inc. Earnings Per Share (Basic)
MBX Biosciences, Inc. (MBX) reported Earnings Per Share (Basic) of -$0.78 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- MBX Biosciences, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.78.
- MBX Biosciences, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.50.
- MBX Biosciences, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.49.
- MBX Biosciences, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.63.
- MBX Biosciences, Inc. earnings per share, basic for fiscal 2025 was -$2.38.
- MBX Biosciences, Inc. earnings per share, basic for fiscal 2024 was -$5.82.
- MBX Biosciences, Inc. earnings per share, basic for fiscal 2023 was -$31.96.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.78 10-Q · filed 2026-08-06 | -$1.29 10-Q · filed 2026-08-06 | -$1.78 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.50 10-Q · filed 2026-05-07 | -$1.00 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.60 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.18 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.49 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.10 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.38 10-K · filed 2026-03-12 |
| 2025-09-30 | -$0.63 10-Q · filed 2025-11-06 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.93 10-Q · filed 2025-11-06 | -$2.39 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.58 10-Q · filed 2026-08-06 | -$1.30 10-Q · filed 2026-08-06 | -$1.76 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$2.88 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.71 10-Q · filed 2026-05-07 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.35 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.93 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.46 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$3.60 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$5.82 10-K · filed 2026-03-12 |
| 2024-09-30 | -$2.78 10-Q · filed 2025-11-06 | -$8.75 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$15.42 10-Q · filed 2025-11-06 | -$21.81 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$12.62 10-Q · filed 2025-08-07 | -$22.93 10-Q · filed 2025-08-07 | -$30.83 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$40.30 derived: net income ÷ weighted average shares · filed 2025-08-07 |
| 2024-03-31 | -$10.26 10-Q · filed 2025-05-12 | -$18.05 derived: net income ÷ weighted average shares · filed 2025-05-12 | -$27.43 derived: net income ÷ weighted average shares · filed 2025-05-12 | |
| 2023-12-31 | -$7.73 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$17.08 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$31.96 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$9.40 10-Q · filed 2024-11-07 | -$24.28 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |